HUMAN LYMPHOKINE-ACTIVATED KILLER CELLS

人类淋巴细胞因子激活的杀伤细胞

• 批准号: 3615774
• 负责人: JANET H RANSOM
• 金额: $ 9.62万
• 依托单位: ADVANCED BIOSCIENCE LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-03-15 至 1991-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3615774
• 关键词: antibody dependent killer cell; human subject; human therapy evaluation; interleukin 2; neoplasm /cancer immunotherapy

This contract shall provide lymphokine-activated killer (LAK) cells for use by the Surgery Branch, NCI in on-going clinical trials. Production of human LAK cells are to be performed for 3 patients per week. These cells will be derived from the patients' peripheral blood by multiple leukopheresis and will be supplied by the Surgery. Each patient that is leukopheresed will yield approximately 3-7 X 1010 cells daily. The number of patients and any modifications of cell activation will be at the discretion of the Project Officer.

该合同将提供淋巴因子激活杀伤（LAK）细胞 供 NCI 外科分部用于正在进行的临床试验。 将为 3 名患者进行人类 LAK 细胞的生产 每周。 这些细胞将来自患者的 通过多次白细胞分离术获取外周血，并由 手术。 每个接受白细胞分离的患者都会产生 每天大约 3-7 X 1010 个细胞。 患者人数和 细胞激活的任何修改将由 项目官员。